MA34059B1 - Thérapie anti-angiogénique pour le traitement du cancer des ovaires - Google Patents

Thérapie anti-angiogénique pour le traitement du cancer des ovaires

Info

Publication number
MA34059B1
MA34059B1 MA35198A MA35198A MA34059B1 MA 34059 B1 MA34059 B1 MA 34059B1 MA 35198 A MA35198 A MA 35198A MA 35198 A MA35198 A MA 35198A MA 34059 B1 MA34059 B1 MA 34059B1
Authority
MA
Morocco
Prior art keywords
treatment
ovarian cancer
angiogenic therapy
cancer
present
Prior art date
Application number
MA35198A
Other languages
Arabic (ar)
English (en)
Inventor
Jakob Dupont
Cornelia Irl
Original Assignee
Genentech Inc
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44476669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34059(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc, Hoffmann La Roche filed Critical Genentech Inc
Publication of MA34059B1 publication Critical patent/MA34059B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q99/00—Subject matter not provided for in other groups of this subclass
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • General Business, Economics & Management (AREA)
  • General Physics & Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • Business, Economics & Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne en général le traitement de maladies et de conditions pathologiques avec des anticorps anti-vegf. De manière plus spécifique, la présente invention concerne le traitement de patients humains susceptibles de cancer ou chez qui un cancer a été diagnostiqué avec un anticorps anti-vegf, de préférence en combinaison avec un ou plusieurs agents antitumoraux supplémentaires pour le traitement du cancer des ovaires.
MA35198A 2010-02-23 2011-02-22 Thérapie anti-angiogénique pour le traitement du cancer des ovaires MA34059B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30709510P 2010-02-23 2010-02-23
US35123110P 2010-06-03 2010-06-03
US36005910P 2010-06-30 2010-06-30
US201161439819P 2011-02-04 2011-02-04
PCT/US2011/025651 WO2011106300A2 (fr) 2010-02-23 2011-02-22 Thérapie anti-angiogénique pour le traitement du cancer des ovaires

Publications (1)

Publication Number Publication Date
MA34059B1 true MA34059B1 (fr) 2013-03-05

Family

ID=44476669

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35198A MA34059B1 (fr) 2010-02-23 2011-02-22 Thérapie anti-angiogénique pour le traitement du cancer des ovaires

Country Status (20)

Country Link
US (7) US8778340B2 (fr)
EP (3) EP2539367A2 (fr)
JP (6) JP2013520442A (fr)
KR (4) KR20190143480A (fr)
CN (2) CN110227154A (fr)
AR (1) AR080244A1 (fr)
AU (5) AU2011221229B2 (fr)
BR (1) BR112012020700A8 (fr)
CA (2) CA2787952C (fr)
CL (1) CL2012002326A1 (fr)
CO (1) CO6592072A2 (fr)
IL (2) IL221058B (fr)
MA (1) MA34059B1 (fr)
MX (3) MX2012009554A (fr)
PH (1) PH12016501728A1 (fr)
RU (1) RU2012140447A (fr)
SG (2) SG183414A1 (fr)
TW (2) TWI457135B (fr)
UA (1) UA114277C2 (fr)
WO (1) WO2011106300A2 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US8858941B2 (en) 2011-09-23 2014-10-14 Oncomed Pharmaceuticals, Inc. VEGF/DLL4 binding agents and uses thereof
SI2825558T1 (sl) * 2012-03-13 2019-08-30 F. Hoffmann-La Roche Ag Kombinirana terapija za zdravljenje raka jajčnikov
PE20150361A1 (es) 2012-07-13 2015-03-14 Roche Glycart Ag Anticuerpos biespecificos anti-vegf/anti-ang-2 y su utilizacion en el tratamiento de enfermedades vasculares oculares
JP6464085B2 (ja) * 2012-08-07 2019-02-06 ジェネンテック， インコーポレイテッド 神経膠芽腫の治療のための併用療法
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
MX2016010067A (es) 2014-02-10 2016-10-07 Merck Patent Gmbh INHIBICION DIRIGIDA DEL FACTOR DE CRECIMIENTO TRANSFORMADOR ß (TGF ß).
PT3127545T (pt) * 2014-04-04 2020-07-20 Taiho Pharmaceutical Co Ltd Fármaco antitumoral que contém composto de taxano e potenciador de efeito antitumoral
AU2015256052A1 (en) * 2014-05-07 2016-11-10 Medimmune, Llc Methods of using anti-Ang2 antibodies
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016011052A1 (fr) 2014-07-14 2016-01-21 Genentech, Inc. Méthodes diagnostiques et compositions pour le traitement du glioblastome
JP2017535548A (ja) * 2014-11-14 2017-11-30 ジェネンテック， インコーポレイテッド Ｖｅｇｆアンタゴニストの応答の予測
CN108601828B (zh) 2015-09-17 2023-04-28 伊缪诺金公司 包含抗folr1免疫缀合物的治疗组合
US11339213B2 (en) 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
TW201713360A (en) * 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
IL290457B1 (en) 2015-12-30 2024-10-01 Kodiak Sciences Inc Antibodies and their conjugates
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
EP3272771A1 (fr) * 2016-07-22 2018-01-24 Centre National De La Recherche Scientifique Traitement destiné à être utilisé pour prévenir les métastases chez un sujet exposé à un traitement anticancéreux induisant l'activation p38
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
WO2019184920A1 (fr) * 2018-03-26 2019-10-03 上海易乐生物技术有限公司 Utilisation d'un régulateur de probdnf dans les maladies associées aux lymphocytes b
CA3157509A1 (fr) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Procedes de traitement d'un trouble oculaire
CN115814076A (zh) * 2021-07-01 2023-03-21 江苏先声药业有限公司 抗人vegf抗体与化药联用在制备治疗卵巢癌的药物中的应用
WO2023196153A1 (fr) * 2022-04-04 2023-10-12 Merck Sharp & Dohme Llc Méthodes de traitement du cancer, d'une maladie infectieuse ou d'une infection à l'aide d'une association d'un antagoniste de tigit, d'un antagoniste de pd-1 et d'un antagoniste de vegf

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US991302A (en) * 1910-03-28 1911-05-02 Frederick G Hepburn Waste-supporter.
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1989006692A1 (fr) 1988-01-12 1989-07-27 Genentech, Inc. Procede de traitement de cellules tumorales par inhibition de la fonction receptrice du facteur de croissance
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
EP0617706B1 (fr) 1991-11-25 2001-10-17 Enzon, Inc. Proteines multivalentes de fixation aux antigenes
CA2372813A1 (fr) 1992-02-06 1993-08-19 L.L. Houston Proteine fixatrice biosynthetique pour marqueur du cancer
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
DE69233803D1 (de) 1992-10-28 2011-03-31 Genentech Inc Verwendung von vaskulären Endothelwachstumsfaktor-Antagonisten
DE69329503T2 (de) 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
CN100360184C (zh) 1995-07-27 2008-01-09 基因技术股份有限公司 稳定等渗的冻干蛋白质制剂
US5730977A (en) 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
DK1695985T3 (da) 1997-04-07 2011-06-14 Genentech Inc Fremgangsmåde til dannelse af humaniserede antistoffer ved tilfældig mutagenese
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
DK0973804T3 (da) 1997-04-07 2007-05-07 Genentech Inc Anti-VEGF-antistoffer
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
AU757627B2 (en) 1997-06-24 2003-02-27 Genentech Inc. Methods and compositions for galactosylated glycoproteins
ATE419009T1 (de) 1997-10-31 2009-01-15 Genentech Inc Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
DK2180007T4 (da) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
KR20060067983A (ko) 1999-01-15 2006-06-20 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
PT1240337E (pt) 1999-12-24 2007-01-31 Genentech Inc Métodos e composições para prolongar as meias-vidas de eliminação de compostos bioactivos
EP1272647B1 (fr) 2000-04-11 2014-11-12 Genentech, Inc. Anticorps multivalents et leurs utilisations
ATE489395T1 (de) 2000-12-12 2010-12-15 Medimmune Llc Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
NZ592087A (en) 2001-08-03 2012-11-30 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
AU2002337935B2 (en) 2001-10-25 2008-05-01 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
MXPA05012723A (es) 2003-05-30 2006-02-08 Genentech Inc Tratamiento con anticuerpos anti-vgf.
WO2005044853A2 (fr) 2003-11-01 2005-05-19 Genentech, Inc. Anticorps anti-vegf
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
GT200500155A (es) * 2004-06-16 2006-05-15 Terapia del càncer resistente al platino
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
RU2453558C2 (ru) * 2004-09-03 2012-06-20 Дженентек, Инк. Гуманизированные антагонистические антитела против бета7 и их применение
US20070166388A1 (en) 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
KR20140015166A (ko) * 2007-10-30 2014-02-06 제넨테크, 인크. 양이온 교환 크로마토그래피에 의한 항체 정제
WO2010059969A2 (fr) 2008-11-22 2010-05-27 Genentech, Inc. Thérapie antiangiogenèse pour le traitement du cancer du sein

Also Published As

Publication number Publication date
US20230226179A1 (en) 2023-07-20
CN103237810A (zh) 2013-08-07
AR080244A1 (es) 2012-03-21
EP2539367A2 (fr) 2013-01-02
MX2019000425A (es) 2023-04-27
KR101839161B9 (ko) 2022-10-18
EP3064509A3 (fr) 2016-11-02
US20180344847A1 (en) 2018-12-06
JP6184733B2 (ja) 2017-08-23
RU2012140447A (ru) 2014-03-27
IL221058B (en) 2018-04-30
CN110227154A (zh) 2019-09-13
WO2011106300A2 (fr) 2011-09-01
JP2016020354A (ja) 2016-02-04
US8778340B2 (en) 2014-07-15
UA114277C2 (uk) 2017-05-25
CA2787952A1 (fr) 2011-09-01
US20140178371A1 (en) 2014-06-26
PH12016501728A1 (en) 2018-02-12
TW201526912A (zh) 2015-07-16
KR20180028561A (ko) 2018-03-16
AU2017204320A1 (en) 2017-07-13
BR112012020700A8 (pt) 2018-01-02
AU2019203466A1 (en) 2019-06-06
SG10201401123VA (en) 2014-08-28
JP2013520442A (ja) 2013-06-06
KR20130010884A (ko) 2013-01-29
KR102104197B1 (ko) 2020-04-24
SG183414A1 (en) 2012-09-27
CA2787952C (fr) 2016-07-26
TWI457135B (zh) 2014-10-21
KR102104197B9 (ko) 2022-10-21
EP3064509A2 (fr) 2016-09-07
MX2012009554A (es) 2012-11-23
AU2017204320B2 (en) 2019-02-21
US20110206662A1 (en) 2011-08-25
AU2015210479A1 (en) 2015-09-03
AU2019210484A1 (en) 2019-08-15
EP3696194A1 (fr) 2020-08-19
CL2012002326A1 (es) 2012-11-30
US20170143826A1 (en) 2017-05-25
KR20180135101A (ko) 2018-12-19
CO6592072A2 (es) 2013-01-02
BR112012020700A2 (pt) 2017-03-21
US20210052728A1 (en) 2021-02-25
TW201138819A (en) 2011-11-16
KR20190143480A (ko) 2019-12-30
CA2930248A1 (fr) 2011-09-01
WO2011106300A3 (fr) 2011-12-15
KR101839161B1 (ko) 2018-03-16
TWI619509B (zh) 2018-04-01
US20160279241A1 (en) 2016-09-29
AU2011221229B2 (en) 2015-06-18
IL258612B (en) 2022-01-01
AU2011221229A1 (en) 2012-08-16
MX369170B (es) 2019-10-30
JP2018199683A (ja) 2018-12-20
JP2020196719A (ja) 2020-12-10
IL258612A (en) 2018-06-28
JP2013173775A (ja) 2013-09-05
JP2017193551A (ja) 2017-10-26

Similar Documents

Publication Publication Date Title
MA34059B1 (fr) Thérapie anti-angiogénique pour le traitement du cancer des ovaires
EA201291260A1 (ru) Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo
MA34555B1 (fr) Nouvelles protéines de liaison à un antigène
MA38183A1 (fr) Composés pyrrolopyrimidines en tant qu'inhibiteurs de kinase
PH12014502507A1 (en) Anti-angiogenesis therapy for the treatment of breast cancer
EA201491006A1 (ru) Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo
TR201904980T4 (tr) Bir B-Raf inhibitörü, bir EGFR inhibitörü ve isteğe bağlı olarak bir PI3K-alfa inhibitörü içeren farmasötik kombinasyonlar.
EA201390506A1 (ru) Полипептиды, которые связывают компонент с5 комплемента человека
MA39094A1 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
EA202090031A3 (ru) Человеческие антитела против gfr3 и способы их применения
UA116772C2 (uk) Виділене моноклональне антитіло або його імунологічно-активний фрагмент, що зв'язується з cd47
MA44645B1 (fr) Traitement combiné d'un anticorps anti-cd20 avec un inhibiteur de bcl-2 et un inhibiteur de mdm2
EA201490717A1 (ru) АНТИТЕЛА К ErbB3 И ИХ ПРИМЕНЕНИЕ
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper
MA32566B1 (fr) Anticorps neutralisant les cytomégalovirus humains et leurs utilisations
MA35165B1 (fr) Induction de tolérance immune par utilisation de méthotrexate
MA33470B1 (fr) Polythérapie à base d'un anticorps afucosylé anti-cd20 et de fludarabine et/ou mitoxantrone
MX342676B (es) Anticuerpos anti-cd52 humanizados.
EA201400996A1 (ru) Комбинированная терапия для лечения рака яичника
MA35281B1 (fr) Dosage et administration d'anticorps anti-erbb3 en combinaison avec le paclitaxel pour le traitement de cancers gynécologiques
MA31265B1 (fr) Traitement du cancer au moyen de l'il-18 humaine combinee a un anticorps anti-cd20
MA33579B1 (fr) Thérapie anti-angiogenèse pour le traitement d'un cancer du sein précédemment traité
BR112014018374A8 (pt) Método para predizer a resposta d eum paciente com câncer, kit, anticorpo, método para o tratamento do câncer e composição farmacêutica
MX2013002718A (es) Composiciones de anticuerpo anti-vegfr-3.
MX2013010367A (es) Composiciones y metodos para la terapia y diagnostico de influenza.